Explore our library of Olink application-related articles! Use the drop-down menu below to filter on specific categories of content.
find out more about how the Olink platform is being used in the drug discovery and development space by reading any of the articles listed below.
Proteomics in drug development
Incomplete knowledge of the real-time biology underlying disease and drug action can drive up costs and time in drug development. Protein biomarkers, along with other omics markers, can be used to predict response, stratify patient populations, and provide insights into the biology of disease.
Diagnostic and prognostic biomarkers for ATTRv amyloidosis
Protein biomarker discovery with Olink identifies a key protein for a rare, progressively debilitating neurological disease that could be a biomarker for diagnosis, prognosis and drug response.
View from the inside – SCALLOP pQTL CVD I study
SCALLOP founder, Anders Mälarstig, talks about the consortium’s first major combined study, which was recently made available on bioRxiv
SCALLOP publication in Nature Metabolism
SCALLOP consortium study in Nature Metabolism identifies protein quantitative trait loci (pQTL) for 90 cardiovascular proteins in over 30,000 individuals.